Rheumatology International

, Volume 32, Issue 7, pp 1963–1965 | Cite as

Successful treatment of SAPHO syndrome with severe spinal disorder using entercept: a case study

Original Article
First Online:
Received:
Accepted:

Abstract

SAPHO syndrome (synovitis, acne, pustulosis, hyperostosis, and osteitis) is a rare disease. Presently, there is no treatment guideline for this illness. Several studies suggested entercept, a novel biological agent against tumor necrosis factor-alpha, is effective in treating SAPHO syndrome. We report a case in which the clinical conditions of a middle-aged female patient diagnosed with SAPHO syndrome, with noted spinal disorder, improved significantly after receiving entercept treatment. The patient remained stable after 3-month follow-up.

Keywords

SAPHO syndrome Tumor necrosis factor-alpha Entercept 
This is a preview of subscription content, log in to check access.

References

  1. 1.
    Wagner AD, Andresen J, Jendro MC et al (2002) Sustained response to tumor necrosis factor alpha-blocking agents in two patients with SAPHO syndrome. Arthritis Rheum 46(7):1965–1968PubMedCrossRefGoogle Scholar
  2. 2.
    Pennanen N, Lapinjoki S, Urtti A et al (1995) Effect of liposomal and free bisphosphonates on the IL-1 beta, IL-6 and TNF alpha secretion from RAW 264 cells in vitro. Pharm Res 12(6):916–922PubMedCrossRefGoogle Scholar
  3. 3.
    Ichikawa J, Sato E, Haro H et al (2009) Successful treatment of SAPHO syndrome with an oral bisphosphonate. Rheum Int 29(6):713–715CrossRefGoogle Scholar
  4. 4.
    Alexis AF, Strober BE (2005) Off-label dermatologic uses of anti-TNF-a therapies. J Cutan Med Surg 9(6):296–302PubMedCrossRefGoogle Scholar
  5. 5.
    Massara A, Cavazzini PL, Trotta F (2006) In SAPHO syndrome anti-TNF-a therapy may induce persistent amelioration of osteoarticular complaints, but may exacerbate cutaneous manifestations. Rheumatology 45(6):730–733PubMedCrossRefGoogle Scholar
  6. 6.
    Olivieri I, Padula A, Ciancio G et al (2002) Successful treatment of SAPHO syndrome with infliximab: report of two cases. Ann Rheum Dis 61(4):375–376PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  1. 1.Department of CardiologyAerospace Central HospitalBeijingChina
  2. 2.Department of Rheumatology and ImmunologyPeking University Third HospitalBeijingChina

Personalised recommendations